Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Imbruvica in Indian Patients with CLL or MCL
NCT03190330Phase 4Completed
- Sponsor
- Johnson & Johnson
- Start
- Jun 2019
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of ibrutinib in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL), sponsored by Johnson & Johnson. Primary endpoints: Treatment Emergent Adverse Events up to 13 months and Treatment Emergent Serious Adverse Events up to 13 months. Started Jun 2019; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT03190330.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03190330.